Literature DB >> 17158939

Caspofungin in combination with amphotericin B against Candida parapsilosis.

Francesco Barchiesi1, Elisabetta Spreghini, Serena Tomassetti, Daniele Giannini, Giorgio Scalise.   

Abstract

Candida parapsilosis has emerged as an important nosocomial pathogen. In the present study, a checkerboard broth microdilution method was performed to investigate the in vitro activities of caspofungin (CAS) in combination with amphotericin B (AMB) against three clinical isolates of C. parapsilosis. Although there was a significant reduction of the MIC of one or both drugs used in combination, an indifferent interaction (fractional inhibitory concentration index greater than 0.50 and less than or equal to 4.0) was observed in 100% of cases. This finding was confirmed by killing curve studies. By a disk diffusion assay, the halo diameters produced by antifungal agents in combination were often significantly greater than those produced by each drug alone. Antagonism was never observed. In a murine model of systemic candidiasis, CAS at either 0.25 or 1 mg/kg/day combined with AMB at 1 mg/kg/day was significantly more effective than each single drug at reducing the colony counts in kidneys. Higher doses of the echinocandin (i.e., 5 and 10 mg/kg/day) combined with the polyene did not show any advantage over CAS alone. Overall, our study showed a positive interaction of CAS and AMB against C. parapsilosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158939      PMCID: PMC1803114          DOI: 10.1128/AAC.00880-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 7.  Current treatment strategies for disseminated candidiasis.

Authors:  Brad J Spellberg; Scott G Filler; John E Edwards
Journal:  Clin Infect Dis       Date:  2005-12-02       Impact factor: 9.079

8.  International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

Authors:  Shawn A Messer; Ronald N Jones; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

9.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

10.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

View more
  14 in total

1.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.

Authors:  Carolina Serena; Marçal Mariné; Guillermo Quindós; Alfonso J Carrillo; J F Cano; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

3.  Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yurdanur Akgun
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

4.  Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yasemin Oz
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

Review 5.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

6.  Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.

Authors:  Yasemin Oz; Ilknur Dag; Nuri Kiraz
Journal:  Mycopathologia       Date:  2011-08-13       Impact factor: 2.574

7.  Novel method for evaluating in vitro activity of anidulafungin in combination with amphotericin B or azoles.

Authors:  R Teixeira-Santos; R Rocha; A Moreira-Rosário; M Monteiro-Soares; E Cantón; A G Rodrigues; C Pina-Vaz
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

8.  Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.

Authors:  Andreas H Groll; Gerda Silling; Charlotte Young; Rainer Schwerdtfeger; Helmut Ostermann; Werner J Heinz; Joachim Gerss; Hedwig Kolve; Claudia Lanvers-Kaminsky; João Paulo Vieira Pinheiro; Sibylle Gammelin; Oliver A Cornely; Gudrun Wuerthwein
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 9.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.

Authors:  Dimitra Dimopoulou; Georgios Hamilos; Maria Tzardi; Russell E Lewis; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.